Annual Analysis of Pharmaceutical R&D Trends in 2022

"The pharmaceutical industry has gone through an extraordinary path in the past two years and is retooling," said Mr Ian Llo.

The untraceable new crown epidemic that broke out two years ago has had a devastating impact on all walks of life, and the pharmaceutical industry is no excepti.

.

Maybe you can find the answer her.

The global R&D pipeline broke the 20,000 mark for the first time 1527 new species added in 2022

According to the white paper, as of January 2022, the number of global drug research and development pipelines in 2022 has reached 20,109, and the pipeline scale has exceeded 20,000 for the first time; an increase of 22% over the same period in 2021, the number of new varieties has reached 1,527, and the growth rate is 2021 Double the annual growth rate (76% in 2021), well above the 25% average over the past five years, and reaching a five-year pe.

Image source: "Annual Analysis of Pharmaceutical R&D Trends in 2022" White Paper

In fact, according to the white paper, the Pharmaprojects database includes 6,343 new drug candidates in 2021, far exceeding the 5,544 added in 2020 and the 4,730 added in 201Among them, 38% of the drugs were anticancer drugs, and neurological drugs ranked second with 17%; anti-infective drugs, mainly new crown-related drugs, only ranked third with a proportion of 1

From the perspective of the drug development stage, the substantial growth of the pipeline scale is mainly concentrated in the preclinical stage, with a growth rate of 1

Image source: "Annual Analysis of Pharmaceutical R&D Trends in 2022" White Paper

Competition of Top Pharmaceutical R&D Enterprises

Hengrui and Fosun entered the TOP25 list for the first time

The formation of the scale of drug pipelines is a summary of the pipeline scales of global drug R&D compani.

Image source: "Annual Analysis of Pharmaceutical R&D Trends in 2022" White Paper

There were no new faces among the top 15 companies on the li.

Among the top 10 pharmaceutical companies, Pfizer, AstraZeneca, Sanofi, and Eli Lilly have all risen in ranking except for Merck and Johnson & Johnson, with AstraZeneca rising the fastest, jumping from ninth place last year to Sixth place this ye.

It is worth mentioning that, for the first time, a Chinese pharmaceutical company broke into the top TOP25 pharmaceutical company rankings, becoming a milestone moment in the history of Chinese pharmaceutical research and developme.

A growth rate of 23%

In the drug development ecosystem, giant pharmaceutical companies have made great contributions to the development of new dru.

And in-depth specific research areas, especially from the perspective of therapeutic areas and therapeutic methods, which areas are the most sought after?

In terms of therapeutic areas, anti-tumor drugs continued to rank first, with 7,772 drugs under development this year, a year-on-year increase of 1
The third-ranked anti-infective drugs had a moderate growth rate of 7% this ye.

The white paper pointed out that this shows that the 24% growth caused by the new crown virus last year was a temporary phenomenon, and it also shows that the product pipeline is continuing to grow, rather than falli.

Among them, the development of "anti-cancer and immune" drugs is the most popular, with the number of active compounds accounting for the largest share for four consecutive years, a year-on-year increase of 1
What is interesting is that the gene therapy, which continues to maintain the third place, has a growth rate of 23% in the number of active compounds, which is the fastest growth rate compared to other treatment typ.

Image source: "Annual Analysis of Pharmaceutical R&D Trends in 2022" White Paper

In fact, cell and gene therapy has risen rapidly in recent years after nearly 10 years of silence, and has become the focus of the indust.

Especially in the past 5 years, the number of cell and gene therapy has shown an explosive growth tre.

As of January 2022, the number of cell therapy and gene therapy drugs has exceeded 2,000, and most of them are still in the clinical research sta.

Among them, AAV is the most commonly used viral vector in gene therapy, and T cells are the most commonly used in cell thera.

Image source: "Annual Analysis of Pharmaceutical R&D Trends in 2022" White Paper

With the gradual rise of China's drug research and development, China's deployment in cutting-edge therapeutic areas has rapidly increas.

At present, China ranks second in the world in the number of registered cell therapy clinical studies, including CAR-T, NK cells, BCMA targeted therapy and other fiel.

At present, two CAR-T therapies have been approved in China, which are Fosun's Akilenx injection and WuXi Junuo's Ruikiolanxe injecti.

Not long ago, the targeted BCMA cell therapy Shidaquiorense developed by Legend Bio and Johnson & Johnson was approved by the FDA for marketi.

What are the popular targets?

PD-L1, CD19, CD

In terms of drug research and development targets, as of January 2022, the total number of drug targets under development in the world has reached 1,952, nearly 100 more than last year's 1,858 targets, a record high, and a staggering 131 new drug targets in 202.

The protein target of the Top 25 drugs in 2022 is CD3E, which replaces HER2, which has won the top spot for two consecutive yea.

The number of drugs will increase from 149 in 2021 to 19And its similar PD-1 pipeline is also expandi.

At the same time, the CD19 target, which is widely used in CAR-T cell therapy, has also locked in the top five positio.

The top seven targets are all used in cancer therapy, and some of them have only been proven for drug development in recent yea.

Surprisingly, serotonin receptor 2A, a relatively traditional drug target for the treatment of psychosis, depression and anxiety disorders, has 43 new drugs disclosed in 2021, and the target ranking jumped from 23rd to 10.

Image source: "Annual Analysis of Pharmaceutical R&D Trends in 2022" White Paper Summary

Looking at the overall situation, although the new crown epidemic has brought various difficulties to the research and development of new drugs; it has not hindered the development of the indust.

Global pharmaceutical R&D has shown a positive development trend in terms of R&D scale, number of sponsors, R&D progress, and therapeutic are.

In particular, Chinese pharmaceutical R&D is emerging as a vigorous force, expanding its influence in the global R&D landsca.

However, for a long time, some Chinese pharmaceutical companies have faced key problems such as lack of source innovation and weak R&D infrastructu.

China's pharmaceutical innovation and R&D still has a long way to .

Especially under the pressure of pharmaceutical reform policies such as centralized drug procurement and innovative drug medical insurance negotiation, Chinese pharmaceutical companies still need to continue to innovate and transform; and due to the limited domestic market and the accumulation of drug target research and development, China's innovative drugs still need to continue to be in line with international standar.

Seek differentiation, go out and seek a larger mark.

Literature: "Annual Analysis of Pharmaceutical R&D Trends in 2022" White Paper